Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS — StellaPhase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(223 sites)
United States
Research Site, Alexander City, Alabama Research Site, Birmingham, Alabama Research Site, Fairhope, Alabama Research Site, Huntsville, Alabama Research Site, Mobile, Alabama Age range
45 Years and older
Last updated January 2026